Study Published in Antimicrobial Agents and Chemotherapy Finds Antifungal Compound VT-1598 Developed by Mycovia Pharmaceuticals Demonstrates In Vitro and In Vivo Activity Against Deadly Candida Auris Fungus

Durham, N.C. – April 11, 2019 – Mycovia Pharmaceuticals, a developer of breakthrough drugs in women’s health, today announced that oral drug candidate VT-1598 has shown in vitro and in vivo activity against Candida auris, an emerging multi-drug resistant fungal pathogen that presents a serious global health threat. NovaQuest Capital Management formed Mycovia in 2018 and recently acquired VT-1598, which Mycovia is developing to combat serious fungal pathogens. The results of the study on Candida auris were published in the March issue of Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology.